explore -WSS

explore

author：knowledge 2025-08-26 10:52:06 - browse：72

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Listen: A conversation with researcher Kevin Esvelt on biosecurity

WSS

Liver decline slowed by off

Eyeing GLP

Eyeing GLP

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Study finds gene variants tied to breast cancer risk in Black women

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Virginia high school admissions case could be legal follow

Addressing health care workers' trauma can help fight burnout

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Digital health: a case of mistaken identity

At least 13 dead in Texas as scorching temps continue

Listen: A conversation with researcher Kevin Esvelt on biosecurity

The cancer drug shortage isn’t new — and neither are the solutions

Pope greeted like rockstar, appears revitalized at 'Catholic Woodstock' in Portugal

How to save PrEP access — and even expand it

Lifetime voting ban for felony convictions struck down in Mississippi

leisure time

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Rock icon Freddie Mercury pre

Medical mystery: When an infection after surgery isn’t what it seems

At flashy new research hub, AstraZeneca lays out ambitious growth goals

H5N1 virus can be tracked in retail milk, scientists say

Scientists find bacteria from stomach of ancient iceman

hotspot

leisure time

knowledge

Wikipedia